| Pre Clinical | Phase 1 | Phase 2 | Phase 3 | |
|---|---|---|---|---|
NuThrax™ (AV7909)Anthrax Vaccine Candidate (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant) *Phase 3 Study: First subject enrollment targeted for 2019 NuThrax™ (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant) is being studied for use as a third generation anthrax vaccine. This candidate consists of BioThrax® (Anthrax Vaccine Adsorbed) in combination with a novel immunostimulatory compound, CPG 7909. Active Clinical Trials
Completed Clinical Trials |
2019* | |||
FLU-IGIVSeasonal Influenza Therapeutic Candidate Hyperimmune Platform **Phase 3 Study: First subject enrollment targeted for 2019 |
2019** | |||
VLA1601Zika Virus Candidate Injectable Purified, Inactivated Zika Virus Vaccine |
||||
ZIKV-IGZika Therapeutic Candidate Hyperimmune Platform **Phase 1 Study: First subject enrollment targeted for 2018 |
2018** | |||
UNI-FLUUniversal Influenza Vaccine Candidate Injectable Nanoparticle Universal Influenza Vaccine |
||||
EBX-205Broad-Spectrum Antibiotic Candidate Oral Topoisomerase Inhibitor |
||||
GC-072Burkholderia Therapeutic Candidate Oral Topoisomerase Inhibitor |
||||
FILOVPan-filovirus Therapeutic Candidate (Ebola, Marburg, Sudan) Hyperimmune Platform, Monoclonal Antibody |
||||
EBI-001Iminosugar Antiviral Candidate Oral Glucosidase Inhibitor |
Clinical Trials Resources
To learn more about Clinical Trials, visit the websites below. These sites are maintained by ClinicalTrials.gov, a web-based resource that provides patients, their family members, health care professionals, researchers, and the public with easy access to information on publicly and privately supported clinical studies on a wide range of diseases and conditions. ClinicalTrials.gov is maintained by the National Library of Medicine at the National Institutes of Health.